A new paper, published in Science Translational Medicine, investigated whether levetiracetam, an anti-seizure medication, could form the basis for innovative drug treatments for Alzheimer’s disease.

Synaptics Incorporated (NASDAQ:SYNA) Q2 2026 Earnings Call Transcript February 5, 2026 Synaptics Incorporated beats earnings expectations. Reported EPS is $1.21, expectations were $1.15. Operator: ...

SAN JOSE, Calif. (AP) — SAN JOSE, Calif. (AP) — Synaptics Inc. (SYNA) on Thursday reported a loss of $14.8 million in its fiscal second quarter. The San Jose, California-based company said it had a ...

The 2.6-million-square-foot Terminal One, part of a multibillion-dollar redevelopment of Kennedy Airport, will be nearly as large as the Empire State Building. The 2.6-million-square-foot Terminal One ...

With a massive multi-billion-dollar transformation underway at Terminal B in Houston's George Bush Intercontinental Airport, plans are in the pipeline for the expansion of yet another terminal. A $5.4 ...

HSINCHU, Taiwan--(BUSINESS WIRE)--Edgecore Networks, a wholly owned subsidiary of Accton Technology and a leader in innovative network solutions for enterprises, data centers, and telecommunication ...

Neurodegenerative disorders, most notably Alzheimer’s disease (AD), are marked by progressive cognitive decline and widespread neuronal loss. A growing body of evidence indicates that synaptic ...

Science and Technology on Electronic Test and Measurement Laboratory, North University of China, Taiyuan 030051, China State Key Laboratory of Extreme Environment Optoelectronic Dynamic Measurement ...